Efficacy and safety of simvastatin (alone or in association with cholestyramine). A 1-year study in 66 patients with type II hyperlipoproteinaemia.
Eur Heart J
; 11(2): 149-55, 1990 Feb.
Article
en En
| MEDLINE
| ID: mdl-2178931
ABSTRACT
The effects and safety of simvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, were investigated alone or in association with cholestyramine in 66 patients with hypercholesterolaemia, in a 1-year study. In type IIa hypercholesterolaemia (41 patients), the association was more effective than simvastatin used alone in lowering total cholesterol (37% vs 29%) and LDL-cholesterol (45% vs 37%). In type IIb hypercholesterolaemia (23 patients), the association simvastatin-cholestyramine did not appear more effective than simvastatin used alone. The decrease of apoprotein B was parallel to the LDL-cholesterol decrease. Apoprotein A1 did not change significantly. The long-term safety of simvastatin was good. No lens opacity was noted. The most serious side-effect in our study was myolysis which occurred in two patients with a marked increase in creatine phosphokinase.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Lovastatina
/
Resina de Colestiramina
/
Hiperlipoproteinemia Tipo II
/
Anticolesterolemiantes
Tipo de estudio:
Clinical_trials
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Eur Heart J
Año:
1990
Tipo del documento:
Article
País de afiliación:
Francia